The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...

Medtronic said Monday the U.S. Food and Drug Administration has approved a brain-stimulation device as a treatment for people with Parkinson's disease, a major milestone for the technology.

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. The NASDAQ composite index has been scorching hot since ...